UBS cuts DiaSorin as Roche competition challenges growth outlook
UBS downgraded DiaSorin SpA to “sell” from “neutral” and cut its price target to €55 from €66, citing Roche competition and expectations that Immunodiagnostics and Molecular growth have outpaced competitive reality. UBS estimates adjusted EBIT 2026-27 are 4%-6% below consensus and forecasts lower EPS and revenue growth.
How this was made
The 30-second read
Why it matters
A sell downgrade with a materially lower PT and trimmed EBIT/EPS forecasts can drive further estimate revisions and multiple compression, particularly if other brokers converge on similar competitive assumptions.
Market read
This is a concrete sell-side action with explicit forecast deltas and competitive catalysts, likely to influence near-term positioning in European diagnostics and medtech multiples.
What to watch
The article focuses on UBS modeling gaps versus consensus; it does not quantify whether management can offset competition via mix, service revenue, or faster-than-modeled platform uptake.
Background
UBS frames DiaSorin’s growth outlook as having been overtaken by competitive dynamics, especially Roche’s latent TB and planned Lyme immunoassays, plus China headwinds.
Market effects
Highlights competitive pressure in latent TB and Lyme testing from Roche, potentially resetting growth expectations for connected immunodiagnostics platforms.
China test-fee unification policy assumptions were raised, implying broader margin and volume pressure for diagnostics providers with China exposure.
If Roche’s immunoassay launches gain traction, it can pressure the whole diagnostics competitive set, influencing valuation multiples across European medtech.
Counterpoint
DiaSorin’s installed base and platform adoption could still support incremental demand even if Roche expands its menu, limiting the magnitude of placement-growth risk.
Key entities
- public_companyDiaSorin SpA
UBS downgraded to sell and cut PT to €55, citing above-market immunodiagnostics growth expectations and Molecular platform capture assumptions that UBS deems too optimistic.
- public_companyRoche
Cited as the key competitive threat, with a June 2026 latent TB immunoassay launch in Europe and planned Lyme immunoassays from 2027.
- brokerUBS
Issued the downgrade and estimate cuts, including EBIT and EPS forecast reductions and a lower terminal margin assumption in its DCF.
